drugset / Trial / NCT00798460

Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients

NCT00798460

Phase 4 Terminated 30 enrolled Inje University Bukwang Pharmaceutical · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the optimal antiviral treatment for lamivudine resistant hepatitis B patients.

Timeline

Start
2008-12
Primary completion
2010-06
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clevudine Small molecule 30 mg
Comparator Lamivudine Other / unclassified 100 mg
Comparator Adefovir Unknown 10 mg